A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial

Stacy Moulder, Hailun Li, Molin Wang, William J. Gradishar, Edith A. Perez, Joseph A. Sparano, Michael Pins, Ximing Yang, George W. Sledge

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The epothilone B analogue, ixabepilone, binds to β-tubulin, is effective for taxane-refractory metastatic breast cancer (MBC), and may be given every 3 weeks or weekly. We evaluated the efficacy of weekly ixabepilone (I) plus trastuzumab (T) and carboplatin (C) as first line therapy in HER2 + MBC. Patients with HER2+ (3+ by IHC or FISH amplified) MBC received I (15 mg/m 2 IV) and C (area under the curve, AUC = 2 IV) on days 1, 8, and 15 of a 28-day cycle for a maximum of 6 cycles, plus weekly T (4 mg/kg loading dose then 2 mg/kg IV) during chemotherapy then every 3 weeks (6 mg/kg IV) until disease progression. The primary objective was to determine whether the combination was associated with a response rate (RR) of at least 75%. Fifty-nine patients were treated, and 39 had HER2 overexpression confirmed in a central lab (cHER2+). For all treated patients, objective response occurred in 26 patients (44%; 95% CI 31-58%), median time to progression was 8.2 months (95% CI 6.3-9.9), and median overall survival was 34.7 months (95% CI 25.7 to [not reached]). Results were comparable for cHer2+ cancers. Grade 3-4 adverse events included neutropenia (49%), thrombocytopenia (14%), fatigue (12%), nausea (7%), diarrhea (7%), and neuropathy (7%). One patient died from treatment complications during cycle 1. Weekly ixabepilone and carboplatin plus trastuzumab have an acceptable toxicity profile, but are not likely to be associated with an RR of 75% in HER2+ MBC. Efficacy appears comparable to paclitaxel, carboplatin, and trastuzumab.

Original languageEnglish (US)
Pages (from-to)663-671
Number of pages9
JournalBreast Cancer Research and Treatment
Volume119
Issue number3
DOIs
StatePublished - Feb 2010

Fingerprint

Carboplatin
Breast Neoplasms
Area Under Curve
Tubulin
Paclitaxel
Neutropenia
Thrombocytopenia
Nausea
Fatigue
Disease Progression
Diarrhea
ixabepilone
Trastuzumab
Drug Therapy
Survival
Therapeutics
Neoplasms

Keywords

  • Breast cancer
  • Carboplatin
  • Trastuzumab
  • Weekly ixabepilone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer : An Eastern Cooperative Oncology Group Trial. / Moulder, Stacy; Li, Hailun; Wang, Molin; Gradishar, William J.; Perez, Edith A.; Sparano, Joseph A.; Pins, Michael; Yang, Ximing; Sledge, George W.

In: Breast Cancer Research and Treatment, Vol. 119, No. 3, 02.2010, p. 663-671.

Research output: Contribution to journalArticle

Moulder, Stacy ; Li, Hailun ; Wang, Molin ; Gradishar, William J. ; Perez, Edith A. ; Sparano, Joseph A. ; Pins, Michael ; Yang, Ximing ; Sledge, George W. / A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer : An Eastern Cooperative Oncology Group Trial. In: Breast Cancer Research and Treatment. 2010 ; Vol. 119, No. 3. pp. 663-671.
@article{ece29cb99a864e3ab1eaed9139265b4d,
title = "A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial",
abstract = "The epothilone B analogue, ixabepilone, binds to β-tubulin, is effective for taxane-refractory metastatic breast cancer (MBC), and may be given every 3 weeks or weekly. We evaluated the efficacy of weekly ixabepilone (I) plus trastuzumab (T) and carboplatin (C) as first line therapy in HER2 + MBC. Patients with HER2+ (3+ by IHC or FISH amplified) MBC received I (15 mg/m 2 IV) and C (area under the curve, AUC = 2 IV) on days 1, 8, and 15 of a 28-day cycle for a maximum of 6 cycles, plus weekly T (4 mg/kg loading dose then 2 mg/kg IV) during chemotherapy then every 3 weeks (6 mg/kg IV) until disease progression. The primary objective was to determine whether the combination was associated with a response rate (RR) of at least 75{\%}. Fifty-nine patients were treated, and 39 had HER2 overexpression confirmed in a central lab (cHER2+). For all treated patients, objective response occurred in 26 patients (44{\%}; 95{\%} CI 31-58{\%}), median time to progression was 8.2 months (95{\%} CI 6.3-9.9), and median overall survival was 34.7 months (95{\%} CI 25.7 to [not reached]). Results were comparable for cHer2+ cancers. Grade 3-4 adverse events included neutropenia (49{\%}), thrombocytopenia (14{\%}), fatigue (12{\%}), nausea (7{\%}), diarrhea (7{\%}), and neuropathy (7{\%}). One patient died from treatment complications during cycle 1. Weekly ixabepilone and carboplatin plus trastuzumab have an acceptable toxicity profile, but are not likely to be associated with an RR of 75{\%} in HER2+ MBC. Efficacy appears comparable to paclitaxel, carboplatin, and trastuzumab.",
keywords = "Breast cancer, Carboplatin, Trastuzumab, Weekly ixabepilone",
author = "Stacy Moulder and Hailun Li and Molin Wang and Gradishar, {William J.} and Perez, {Edith A.} and Sparano, {Joseph A.} and Michael Pins and Ximing Yang and Sledge, {George W.}",
year = "2010",
month = "2",
doi = "10.1007/s10549-009-0658-9",
language = "English (US)",
volume = "119",
pages = "663--671",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer

T2 - An Eastern Cooperative Oncology Group Trial

AU - Moulder, Stacy

AU - Li, Hailun

AU - Wang, Molin

AU - Gradishar, William J.

AU - Perez, Edith A.

AU - Sparano, Joseph A.

AU - Pins, Michael

AU - Yang, Ximing

AU - Sledge, George W.

PY - 2010/2

Y1 - 2010/2

N2 - The epothilone B analogue, ixabepilone, binds to β-tubulin, is effective for taxane-refractory metastatic breast cancer (MBC), and may be given every 3 weeks or weekly. We evaluated the efficacy of weekly ixabepilone (I) plus trastuzumab (T) and carboplatin (C) as first line therapy in HER2 + MBC. Patients with HER2+ (3+ by IHC or FISH amplified) MBC received I (15 mg/m 2 IV) and C (area under the curve, AUC = 2 IV) on days 1, 8, and 15 of a 28-day cycle for a maximum of 6 cycles, plus weekly T (4 mg/kg loading dose then 2 mg/kg IV) during chemotherapy then every 3 weeks (6 mg/kg IV) until disease progression. The primary objective was to determine whether the combination was associated with a response rate (RR) of at least 75%. Fifty-nine patients were treated, and 39 had HER2 overexpression confirmed in a central lab (cHER2+). For all treated patients, objective response occurred in 26 patients (44%; 95% CI 31-58%), median time to progression was 8.2 months (95% CI 6.3-9.9), and median overall survival was 34.7 months (95% CI 25.7 to [not reached]). Results were comparable for cHer2+ cancers. Grade 3-4 adverse events included neutropenia (49%), thrombocytopenia (14%), fatigue (12%), nausea (7%), diarrhea (7%), and neuropathy (7%). One patient died from treatment complications during cycle 1. Weekly ixabepilone and carboplatin plus trastuzumab have an acceptable toxicity profile, but are not likely to be associated with an RR of 75% in HER2+ MBC. Efficacy appears comparable to paclitaxel, carboplatin, and trastuzumab.

AB - The epothilone B analogue, ixabepilone, binds to β-tubulin, is effective for taxane-refractory metastatic breast cancer (MBC), and may be given every 3 weeks or weekly. We evaluated the efficacy of weekly ixabepilone (I) plus trastuzumab (T) and carboplatin (C) as first line therapy in HER2 + MBC. Patients with HER2+ (3+ by IHC or FISH amplified) MBC received I (15 mg/m 2 IV) and C (area under the curve, AUC = 2 IV) on days 1, 8, and 15 of a 28-day cycle for a maximum of 6 cycles, plus weekly T (4 mg/kg loading dose then 2 mg/kg IV) during chemotherapy then every 3 weeks (6 mg/kg IV) until disease progression. The primary objective was to determine whether the combination was associated with a response rate (RR) of at least 75%. Fifty-nine patients were treated, and 39 had HER2 overexpression confirmed in a central lab (cHER2+). For all treated patients, objective response occurred in 26 patients (44%; 95% CI 31-58%), median time to progression was 8.2 months (95% CI 6.3-9.9), and median overall survival was 34.7 months (95% CI 25.7 to [not reached]). Results were comparable for cHer2+ cancers. Grade 3-4 adverse events included neutropenia (49%), thrombocytopenia (14%), fatigue (12%), nausea (7%), diarrhea (7%), and neuropathy (7%). One patient died from treatment complications during cycle 1. Weekly ixabepilone and carboplatin plus trastuzumab have an acceptable toxicity profile, but are not likely to be associated with an RR of 75% in HER2+ MBC. Efficacy appears comparable to paclitaxel, carboplatin, and trastuzumab.

KW - Breast cancer

KW - Carboplatin

KW - Trastuzumab

KW - Weekly ixabepilone

UR - http://www.scopus.com/inward/record.url?scp=74849122823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849122823&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0658-9

DO - 10.1007/s10549-009-0658-9

M3 - Article

C2 - 20012354

AN - SCOPUS:74849122823

VL - 119

SP - 663

EP - 671

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -